TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03783793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training App
Description: Mindfulness training in the study was performed using a new app called Wildflowers. With this app participants were able to choose and complete a variety of guided meditations over the 3 week training period. Wildflowers includes guided meditations such as breathing, body scans, and open monitoring practices and also provides didactic content in the form of lessons and information about the benefits of mindfulness training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training With 2048
Description: The training app for the control condition was based on an open source code for a popular cognitive training app called 2048 that is marketed as a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value. Instead of tiles disappearing, as in Candy Crush or other similar grid-sliding games, matching 2 numbered tiles in 2048 combines them into 1 new tile displaying the sum of the previous 2 numbers. For example, two 2-tiles linked side-by-side become a 4-tile, whereas 2 matched 4-tiles become an 8-tile, and so on. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit.
Study: NCT03216577

Intervention type: OTHER
Intervention: Phone interview measuring health-related quality of life variables
Description: A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.

Intervention type: OTHER
Intervention: Phone interview measuring health-related quality of life variables
Description: A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
Study: NCT03243487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: structured adherence management program
Description: Structured adherence management service (PAMS) program and a web-based information program designed for participants beginning positive airway pressure therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard care provided at a VA Sleep Center for participants beginning positive airway pressure therapy
Study: NCT00420238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel)
Description: 50 mg injection once weekly
Study: NCT03524001

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compare VVi mode versus DDD bifocal stimulation through crossover randomization
Description: All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex.Then the leads are connected to CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute.After six months (second follow-up) a clinical and instrumental assessment equal to baseline is performed. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator that plans stimulation mode able to determine the best clinical improved.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Compare VVi mode versus DDD bifocal stimulation through crossover randomization
Description: All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex.Then the leads are connected to CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute.After six months (second follow-up) a clinical and instrumental assessment equal to baseline is performed. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator that plans stimulation mode able to determine the best clinical improved.
Study: NCT01588275

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mandibular repositioning appliance (MRA) (SomnoDent)
Description: bibloc MRA type SomnoDent starting at 70% protrusion of the mandibula
Study: NCT00420238

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04587557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling with social contextual information
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling with social contextual information
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Storytelling without social contextual information
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Storytelling without social contextual information
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Children with ASD
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
Study: NCT02879487

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar needle electrode
Description: Colpotomy during total laparoscopic hysterectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar needle electrode
Description: Colpotomy during total laparoscopic hysterectomy
Study: NCT04592952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin Gene-Related Peptide
Description: Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
Study: NCT02252341

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: N-Acetyl-Cysteine
Description: drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
Study: NCT03558568

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation is an established surgical method for Parkinson's Disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation is an established surgical method for Parkinson's Disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation is an established surgical method for Parkinson's Disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation is an established surgical method for Parkinson's Disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation is an established surgical method for Parkinson's Disease.
Study: NCT03234140

Intervention type: GENETIC
Intervention: Genome Wide Association Studies
Description: Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.

Intervention type: GENETIC
Intervention: Single-nucleotide polymorphisms's genotyping
Description: Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
Study: NCT02081248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consent Form Specific Format 1
Description: The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consent Form Specific Format 2
Description: The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
Study: NCT04564300

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Both groups will perform a standardized training protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training
Description: Both groups will perform a standardized training protocol
Study: NCT03160313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InFuSE
Description: Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education/Group Discussion
Description: Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
Study: NCT03460509

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugammadex
Description: Dose-response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Dose-response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Dose-response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Dose-response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Dose-response
Study: NCT04822805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
Study: NCT04320030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-DPA-714 PET/CT scan
Description: Pretherapeutic \[18F\]-DPA-714 PET/CT scan
Study: NCT01255748

Intervention type: RADIATION
Intervention: Proton Therapy, Photon Therapy, SRS, Brachytherapy
Description: Outcomes Tracking
Study: NCT03250364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multilayer bandage
Description: See arm/group descriptions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double compression bandage
Description: See arm/group descriptions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohesive bandage
Description: See arm/group descriptions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive compression bandage
Description: See arm/group descriptions
Study: NCT04587557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children with ASD
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
Study: NCT03785054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo treatment
Study: NCT04587557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Children with TD
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children with TD
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
Study: NCT03011294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: Standard treatment for sleep apnea

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal strip
Description: Placebo
Study: NCT04443660

Intervention type: OTHER
Intervention: Blood test
Description: Blood samples taken to test levels of autophagy and apoptosis

Intervention type: OTHER
Intervention: Blood test
Description: Blood samples taken to test levels of autophagy and apoptosis

Intervention type: OTHER
Intervention: Blood test
Description: Blood samples taken to test levels of autophagy and apoptosis

Intervention type: OTHER
Intervention: Blood test
Description: Blood samples taken to test levels of autophagy and apoptosis
Study: NCT01474551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
Study: NCT03250364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping bandage
Description: See arm/group descriptions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression
Description: MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg.
Study: NCT02539290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detection of ovulation
Description: Detecting the luteinizing hormone surge using test sticks in a urine sample

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Detection of ovulation
Description: Detecting the luteinizing hormone surge using test sticks in a urine sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine flushing
Description: Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vaginal flushing
Description: Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual intercourse
Description: Sexual intercourse on the day of the intervention and the following day

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sexual intercourse
Description: Sexual intercourse on the day of the intervention and the following day
Study: NCT00129311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: 5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01666847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Milking the umbilical cord before cord clamping
Description: The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
Study: NCT02491229

Intervention type: OTHER
Group type: OTHER
Intervention: Hepafast
Description: Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
Study: NCT02704247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CARDIOSPACE System
Description: * autonomic nervous system test~* tilt test~* ultrasound exploration at rest (heart / vessels)~* laser doppler + iontophoresis test~* sub-maximal exercise test
Study: NCT02432547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted laser therapy
Description: In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
Study: NCT01762709

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The VT 4 ml/kg group
Description: the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The VT 6 ml/kg group
Description: the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
Study: NCT00934076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva plus AT-101
Description: 150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.~Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis.
Study: NCT04629560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miracle Fruit
Description: one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder